Meglumine Cyclic Adenylate(MCA) Injection In Treating Patients With Severe Congestive Heart Failure

Objective: To observe the efficacy and safety of MCA in treating congestive heart failure (CHF).Method: Forty-two patients with CHF were involved in this study and randomly assigned to two groups: (1) MCA group (n=21), (2) Control group (n=21). The baseline clinical characteristics of patients were similar between two groups. Control group received conventional treatment for two weeks. MCA group received conventional treatment plus MCA 180 mg +10% glucose 250 ml ivgtt qd for two weeks. Before and after the treatment heart rate, blood pressure, cardiac functional classes were investigated. CI,SV ,LVEF and FS were examined by UCG, blood test, urine test, biochemical indices (blood glucose, lipid, liver function, renal function, electrolyte) were tested. Result: Compared with those of the control group the decrease of heart rate and NYHA cardiac function class in MCA group was more obvious after 14 days of treatment. CI,SV ,LVEF and FS measured by UCG was much increased in MCA group as compared with that of the control, respectively, [(3.91±0.6) L/min/m2 VS (2.31±0.7) L/min/m2, P<0.01], [(79.71±6.81)ml VS (67.0±10.2)ml, P<0.01], [(0.53±0.18)% VS (0.39±0.21)%, P<0.01], [(24.8±6.4)% VS (18.2±5.37)%, P<0.01].Conclusion: MCA can improve LV function.